The new Chief Medical Officer, Pia Baumann’s, role includes overall responsibility for the continued clinical development of the candidate drug fostroxacitabine bralpamide.
She will be part of the company’s management team and will take up her position on February 20, 2023.
“Her experience in global drug development as well as interaction and cooperation with regulatory authorities, especially in the USA and Japan, will be very important for the continued clinical development of fostrox. In addition, her broad leadership experience from both large and small organizations as well as experience in interacting with the financial market will be of great value to the company,” says Jens Lindberg, CEO at Medivir.
Pia Baumann, who is an MD specialized in oncology and earned her Ph.D. at Karolinska Institute, has substantial experience in drug development in the cancer field, states Medivir. Her experience comes from many years of clinical work at Karolinska Hospital and larger pharmaceutical companies as well as smaller biotech companies where she has developed global product strategies as well as designed and conducted clinical studies in close collaboration with leading clinics. Pia most recently held a position at AstraZeneca as Vice President Medical with global responsibility for the company’s Tagrisso and Lung Cancer franchise. Before that, she held leading, global positions in cancer drug development at Takeda, Incyte and ARIAD Pharmaceuticals.